Kalia Kumud sold $652K of GH

Kalia Kumud (Chief Information Officer) sold 5,000 shares of Guardant Health, Inc. (GH) at $130.41 ($0.65M total) on 2026-06-10.

Original reporting
SEC EDGAR · Kalia Kumud
Published Jun 12, 2026, 8:27 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 12, 2026, 8:28 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$GH
Neutral
medium confidence
Mentioned
$GH
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GHNeutralLow
01

Why it matters

The disclosure updates the insider ownership record and may slightly influence sentiment, but it does not constitute new operational/regulatory/financial guidance.

02

Market read

A ~$652K insider sale is newly disclosed; traders may monitor for follow-on insider activity but should not treat it as a fundamental catalyst.

03

What to watch

The article doesn’t state whether additional insiders sold/bought around the same time, nor does it provide the insider’s total compensation context or whether other transactions occurred after 2026-06-10.

Relevance 5/10Novelty 8/10Timing: filed 2026-06-12 (covers sale dated 2026-06-10)

Background

SEC Form 4 reports an officer’s direct open-market sale of Guardant Health shares.

Company-level read

Ticker impact

$GHNeutralMedium confidence
Context

Guardant Health CIO Kalia Kumud filed an open-market sale of 5,000 shares on 2026-06-10 for ~$652K (Form 4).

Expected impact

Likely minimal near-term impact; any effect would be sentiment-only and typically fades unless follow-on selling accelerates.

Evidence & confidence

The filing is a primary-source insider transaction, but it is not a buy, not tied to a disclosed corporate event, and the article provides no broader fundamental change.

Market effects

No direct sector read-through; this is company-specific insider liquidity/positioning information.

None indicated.

None indicated.

Counterpoint

Insider sales can be pre-planned for diversification or tax/comp liquidity; the absence of a 10b5-1 plan in the filing doesn’t automatically imply negative fundamentals.

Key entities

  • Guardant Health, Inc.

    Public company whose insider transaction is disclosed on Form 4.

  • Kalia Kumud

    Chief Information Officer reporting the sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$GHHighAI 8/10

Why is Guardant Health stock climbing today?

Guardant Health (GH) stock rose 2.5% in pre-market trading after pricing a $500M offering of 0% convertible notes due 2032, with a 35% premium conversion price. The company plans to use proceeds to repurchase $395.2M of existing convertible notes due 2027, optimizing its balance sheet. The move came amid broader market headwinds for growth and tech names.